Loading...
XNASTPST
Market cap41mUSD
Jan 07, Last price  
0.95USD
1D
-0.42%
1Q
-29.99%
Jan 2017
-99.73%
IPO
-99.95%
Name

Tempest Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TPST chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
172.22%
Rev. gr., 5y
1.18%
Revenues
0k
009,735,000277,000653,000295,000000000
Net income
-29m
L-19.81%
-13,510,000-29,044,000-49,520,000-73,219,000-82,260,000-84,578,000-27,192,000-44,568,000-19,118,000-29,550,000-36,778,000-29,491,000
CFO
-27m
L-11.96%
-11,156,000-18,094,000-30,588,000-50,286,000-61,734,000-20,340,000-23,647,000-41,222,000-19,017,000-25,957,000-31,072,000-27,357,000
Earnings
Mar 17, 2025

Profile

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
URL
https://www.tempesttx.com/
IPO date
Oct 04, 2012
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
29,538
36,454
Unusual Expense (Income)
NOPBT
(29,538)
(36,454)
NOPBT Margin
Operating Taxes
1,069
Tax Rate
NOPAT
(29,538)
(37,523)
Net income
(29,491)
-19.81%
(36,778)
24.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
35,602
8,861
BB yield
-52.49%
-66.72%
Debt
Debt current
6,189
1,413
Long-term debt
25,536
32,444
Deferred revenue
Other long-term liabilities
Net debt
(7,505)
2,627
Cash flow
Cash from operating activities
(27,357)
(31,072)
CAPEX
(170)
(562)
Cash from investing activities
(170)
(562)
Cash from financing activities
35,602
11,403
FCF
(27,620)
(46,069)
Balance
Cash
39,230
31,230
Long term investments
Excess cash
39,230
31,230
Stockholders' equity
(165,241)
(135,761)
Invested Capital
213,622
175,986
ROIC
ROCE
EV
Common stock shares outstanding
15,416
11,549
Price
4.40
282.61%
1.15
-78.22%
Market cap
67,831
410.73%
13,281
-33.64%
EV
60,326
15,908
EBITDA
(29,157)
(35,816)
EV/EBITDA
Interest
1,449
1,618
Interest/NOPBT